Explore the Latest Dolutegravir Tenders on Tender Impulse - Your Trusted Global Tender Website
Are you searching for the latest Dolutegravir Tenders from trusted sources across the globe? Tender Impulse is the go-to tender website for businesses seeking verified, timely updates on public tenders, government tenders and business tenders.
With real-time data and smart filters, you can find the most relevant Dolutegravir Tenders issued by ministries, public sector organisations and international procurement agencies - whether you're an SME or a multinational.
All-in-One Platform for Dolutegravir Tenders
- Requests for Proposals (RFPs) & Quotations (RFQs)
- General Procurement Notices (GPNs) & Expressions of Interest (EOIs)
- Prequalification documents, contract awards and amendments
Why Choose Tender Impulse?
- Custom email alerts tailored to your industry.
- Global coverage across 190+ countries and every major sector.
- Instant document access - specifications, BOQs and tender forms.
- Advanced filters by country, industry, deadline, value and procurement type.
Request a free live demo today and explore thousands of Dolutegravir Tenders and beyond.
6878790: TK aims to conclude discount agreements with all suitable pharmaceutical companies in accordance with Section 130c Paragraph 1 SGB V for the active ingredient combination lamivuCountry: GermanyDeadline28 Feb 20276880039TK aims to conclude discount agreements for the active ingredient dolutegravir with all suitable pharmaceutical companies in accordance with Section 130c Paragraph 1 SGB V.Country: GermanyDeadline28 Feb 20278001247Germany Pharmaceutical products Open house Arzneimittelrabattvertrge zum Wirkstoff Dolutegravir ATC J05AJ03Country: GermanyDeadline30 Apr 20278008003Germany Pharmaceutical products Abschluss einer nicht-exklusiven Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff Lamivudin Abacavir Dolutegravir ATC J05AR13 fr die ZeitCountry: GermanyDeadline05 May 20278008065Germany Pharmaceutical products Abschluss einer nicht-exklusiven Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff Dolutegravir Rilpivirin ATC J05AR21 fr die Zeit 01072025Country: GermanyDeadline05 May 20278013024Germany Pharmaceutical products Abschluss einer nicht-exklusiven Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff Lamivudin Dolutegravir ATC J05AR25 fr die Zeit 01072025Country: GermanyDeadline05 May 20278633009Germany Pharmaceutical products Open house Arzneimittelrabattvertrge zum Wirkstoff Lamivudin und Dolutegravir ATC J05AR25Country: GermanyDeadline30 Jun 20278641603Germany Pharmaceutical products Open house Arzneimittelrabattvertrge zum Wirkstoff Lamivudin Abacavir und Dolutegravir ATC J05AR13Country: GermanyDeadline30 Jun 20278646722Open house pharmaceutical discount contracts for the active ingredient lamivudine abacavir and dolutegravir atc j05ar13Country: GermanyDeadline01 Jul 202712433310Germany Pharmaceutical products Open house Arzneimittelrabattvertrge Lamivudin Abacavir und Dolutegravir ATC J05AR13Country: GermanyDeadline03 Apr 202812433930Germany Pharmaceutical products Open house Arzneimittelrabattvertrge Lamivudin und Dolutegravir ATC J05AR25Country: GermanyDeadline03 Apr 202812433980Germany Pharmaceutical products Open house Arzneimittelrabattvertrge Dolutegravir ATC J05AJ03Country: GermanyDeadline03 Apr 202812467862Germany Pharmaceutical products Abschluss einer nicht-exklusiven Rabattvereinbarung nach 130a Abs 8 SGB V zum Wirkstoff Dolutegravir ATC J05AJ03 fr die Zeit 01062026 - 31052028Country: GermanyDeadline05 Apr 202813351694Open house Arzneimittelrabattverträge Dolutegravir und Rilpivirin, ATC J05AR21Country: GermanyDeadline02 Jun 202813364097Open house Arzneimittelrabattverträge zum Wirkstoff Dolutegravir und Rilpivirin, ATC J05AR21Country: GermanyDeadline30 May 202813387309Open house drug discount agreements for the active ingredients dolutegravir and rilpivirine atc j05ar21Country: GermanyDeadline01 Jun 202813484395Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (combination of active ingredients)Country: GermanyDeadline28 Feb 202713484398Open House Originals Discount Agreements 2025-06 - DolutegravirCountry: GermanyDeadline28 Feb 202713542737Suministro de Medicamento Exclusivo-Dolutegravir sodio 50 mg / Lamivudina 300 mg comprimidosCountry: SpainDeadline23 Sep 202613579506Open House Original Discount Agreements 2025-07 - Lamivudine/Abacavir/Dolutegravir (combination of active ingredients)Country: GermanyDeadline28 Feb 202713579507Open House Originals Discount Agreements 2025-06 - DolutegravirCountry: GermanyDeadline28 Feb 2027
